PEscreen® - Preeclampsia Screening Test
Minimally Invasive
Cost Efficient
Early Detection
Easy To Perform
Rapid Test
GLOBAL PREECLAMPSIA STATISTICS
Early diagnosis and timely intervention can lead to a healthier pregnancy
PREECLAMPSIA
A pregnancy related disease characterised by high blood pressure and the presence of protein in urine, Preeclampsia can be fatal to both the mother and the baby. Currently, the rate of this disease in developing countries is seven times higher than that in developed countries.
Based on the time of appearance of clinical symptoms, PE has been classified into early (before 34 weeks) and late onset (after 34 weeks) of gestation. Early onset is associated with high risk to both mother and fetus, whereas late onset may contribute to less severe clinical symptoms.
PEscreen®
An innovative, rapid, minimally-invasive, point-of-care solution for screening preeclampsia. This test can predict the risk of development of preeclampsia in upcoming weeks of gestation based on the levels of a placetal based biomarker.
KIT COMPONENTS
Test Device
Buffer vial
Dropper
Innovatively developed
Preeclampsia Screening Test
What Does The Test Detects?
Detects a protein from a drop of blood in 15 minutes
Where Can You Perform The Test?
Hospitals, Clinics, Path Labs, PHCs
When Can You Perform The Test?
During regular antenatal visits
Who Can Perform The Test?
Doctors, Nurses, Trained ASHA workers and lab technicians
